A phase II study of palbociclib and trastuzumab with or without letrozole in previously treated, postmenopausal patients with HER2-positive metastatic breast cancer.
A phase II randomized, double-blind, study of ipatasertib (GDC-0068), an Akt inhibitor, in combination with paclitaxel as neoadjuvant treatment for patients with early stage triple negative breast...
Addition of the selective anti-HER2 agent ONT-380 to the treatment with capecitabine and trastuzumab in pretreated HER2+ breast cancer patients
Phase III trial of Palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for HR+/HER2-negative early breast cancer
Endocrine therapy interruption to enable conception for young women with ER+ breast cancer
AGATA: SOLTI molecular screening program: a Pilot Study to implement personalized therapy for patients with locally advanced or metastatic breast cancer
Addition of the PI3K/Akt pathway selective inhibitor taselisib to neoadjuvant letrozole in postmenopausal women with HR+ early stage breast cancer
Aiming to understand the molecular aberrations in metastatic breast cancer
Adjuvant olaparib for patients with BRCA1/2-mutated , high-risk HER2-negative breast cancer
Randomized study of fulvestrant in monotherapy vs combined with everolimus or with the mTOR inhibitor AZD2014 in HR+ metastatic breast cancer